<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03403205</url>
  </required_header>
  <id_info>
    <org_study_id>WTX101-301</org_study_id>
    <nct_id>NCT03403205</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease With an Extension Period of up to 60 Months</brief_title>
  <official_title>A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate the Efficacy and Safety of ALXN1840 Administered For 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older With an Extension Period of Up To 60 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101)&#xD;
      administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD)&#xD;
      participants aged 12 and older in the Primary Evaluation Period. In addition, efficacy and&#xD;
      safety will be evaluated during an optional 60-month Extension Period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of 2 cohorts. Cohort 1: Participants who have received SoC therapy for &gt;&#xD;
      28 days and Cohort 2: Participants who are treatment-naïve or who have received SoC therapy&#xD;
      for ≤ 28 days.&#xD;
&#xD;
      All enrolled participants were randomized by cohort in a 2:1 ratio to treatment with ALXN1840&#xD;
      or SoC (either as continued therapy in Cohort 1 or as continued or initial therapy in Cohort&#xD;
      2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Actual">February 24, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>This study is rater-blinded for the Unified Wilson Disease Rating Scale (UWDRS) assessment only.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Mean Area Under The Effect-time Curve (AUEC) Of Directly Measured Non-ceruloplasmin-bound Copper (dNCC)</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>Primary Evaluation Period: Baseline through 48 weeks; Extension Period: Baseline through up to 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In The Unified Wilson Disease Rating Scale (UWDRS) Part II Total Score</measure>
    <time_frame>Primary Evaluation Period: Baseline through 48 weeks; Extension Period: Baseline through up to 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In UWDRS Part III Total Score And Individual Items/Subscales (Arising From A Chair, Gait, Handwriting, And Speech)</measure>
    <time_frame>Primary Evaluation Period: Baseline through 48 weeks; Extension Period: Baseline through up to 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Improvement Scale (CGI-I)</measure>
    <time_frame>Primary Evaluation Period: Baseline through 48 weeks; Extension Period: Baseline through up to 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Clinical Global Impression Severity Scale (CGI-S)</measure>
    <time_frame>Primary Evaluation Period: Baseline through 48 weeks; Extension Period: Baseline through up to 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Model For End-Stage Liver Disease (MELD) Score</measure>
    <time_frame>Primary Evaluation Period: Baseline through 48 weeks; Extension Period: Baseline through up to 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Calculated NCC (cNCC) In Plasma</measure>
    <time_frame>Baseline (Day 1), 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cNCC Responder Rate</measure>
    <time_frame>Primary Evaluation Period: Baseline through 48 weeks; Extension Period: Baseline through up to 60 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Wilson Disease</condition>
  <arm_group>
    <arm_group_label>ALXN1840</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALXN1840 was administered orally for 48 weeks at doses ranging from 15 milligrams (mg) every other day (QOD) up to a titrated dose of 60 mg daily.&#xD;
Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SoC) Medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SoC medication was administered for 48 weeks. Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1840</intervention_name>
    <description>ALXN1840 administered orally in 15 mg tablets</description>
    <arm_group_label>ALXN1840</arm_group_label>
    <other_name>Formerly named WTX101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SoC Therapy</intervention_name>
    <description>Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.</description>
    <arm_group_label>Standard of Care (SoC) Medication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Established diagnosis of WD by Leipzig-Score ≥ than 4&#xD;
&#xD;
          -  Female participants of childbearing potential, if heterosexually active, must be&#xD;
             willing to follow protocol-specified guidance for highly effective contraception&#xD;
             starting at least 6 weeks before the Day 1 visit and continuing through 28 days after&#xD;
             the last dose of either ALXN1840 or SoC&#xD;
&#xD;
          -  Male participants, if heterosexually active, must be willing to follow&#xD;
             protocol-specified guidance for highly effective contraception beginning at Day 1&#xD;
             visit and continuing through 90 days after last dose of either ALXN1840 or SoC&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Decompensated hepatic cirrhosis&#xD;
&#xD;
          -  MELD score &gt; 13&#xD;
&#xD;
          -  Modified Nazer score &gt; 7&#xD;
&#xD;
          -  Clinically significant gastrointestinal bleed within past 3 months&#xD;
&#xD;
          -  Alanine aminotransferase &gt; 2 X upper limit of normal (ULN) for participants treated&#xD;
             for &gt; 28 days with WD therapy (Cohort 1)&#xD;
&#xD;
          -  Alanine aminotransferase &gt; 5 X ULN for treatment-naïve participants or participants&#xD;
             who have been treated for ≤ 28 days (Cohort 2)&#xD;
&#xD;
          -  Marked neurological disease requiring either nasogastric feeding or intensive&#xD;
             inpatient medical care&#xD;
&#xD;
          -  Hemoglobin &lt; 9 grams/deciliter&#xD;
&#xD;
          -  History of seizure activity within 6 months prior to informed consent&#xD;
&#xD;
          -  Pregnant (or women who are planning to become pregnant) or breastfeeding women&#xD;
&#xD;
          -  Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C&#xD;
             virus or seropositivity for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Previous treatment with tetrathiomolybdate&#xD;
&#xD;
          -  Participants with end-stage renal disease on dialysis (chronic kidney disease stage 5)&#xD;
             or creatinine clearance &lt; 30 milliliter/minute&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Swenson, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alexion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Concord</city>
        <zip>NSW 2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>Q47X+XQ</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>2RWV+M4</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Warszawa</city>
        <state>Woj. Mazowieckie</state>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Warsaw</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Moscow</city>
        <zip>115446</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Barcelona</city>
        <zip>H446+P9</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Málaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Bornova</city>
        <state>Izmir</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Ankara</city>
        <zip>06620</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Istanbul</city>
        <zip>1111</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Guildford</city>
        <state>England</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Brixton</city>
        <state>London</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2018</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatolenticular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

